Weixian Yang

Dr. Weixian Yang

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JZJinghan Zeng
Jinghan Zeng
YLYilu Liu
Yilu Liu
TZTianlang Zhao
Tianlang Zhao
JYJiansong Yuan
Jiansong Yuan
WYWeixian Yang
Weixian Yang
MWMan Wang
Man Wang
Objective: We aimed to conduct a meta-analysis of treatments for large vessel coronary artery disease between drug-coated balloons and drug-eluting stents. Method: We searched databases including PubMed, Web of Science, Cochrane, CNKI, and Wanfang, and selected randomized controlled trials (RCTs) or cohort studies which compared drug-coated balloons (DCBs) with drug-eluting stents (DESs). The reference vessel diameter (RVD) should be greater than 2.75 mm. The results of 12 studies with a total of 2634 patients were included in this meta-analysis. Results: The results showed that the DCB group was not inferior to the DES group in terms of the incidence of target lesion revascularization (TLR). (RR = 1.25, 95% CI: [0.84, 1.85], p = 0.27, I2 = 0%), and the incidence of bleeding events in the DCB group was lower than that in the DES group (RR = 0.30, 95% CI: [0.15, 0.59], p = 0.0004). The results also showed that the post-intervention minimal lumen diameter (MLD) in the DCB group was smaller than that in the DES group. (RR = −0.37, 95% CI: [−0.59, −0.16], p = 0.0007), but the follow-up MLD in the DCB group was not less than that in the DES group (RR = −0.03, 95% CI: [−0.14,−0.08], p = 0.61). Additionally the DCB group had less late lumen loss (LLL) compared with the DES group. (RR = −0.31, 95% CI: [−0.60, −0.02], p < 0.0001). Conclusion: This meta-analysis confirms that in the early and late stages after percutaneous coronary intervention (PCI), DCB is not inferior in efficacy and safety to DES for de novo large coronary lesions with RVD > 2.75 mm.

30 August 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
ZSZhiFeng Song
ZhiFeng Song
CDChilie Danzeng
Chilie Danzeng
YJYu Jiang
Yu Jiang
JYJingang Yang
Jingang Yang
WYWeixian Yang
Weixian Yang
YYYuejin Yang
Yuejin Yang
Background: Globally, acute myocardial infarction (AMI) is among the primary causes of mortality. The ideal approach for blood pressure (BP) management for patients experiencing ST-segment elevation myocardial infarction (STEMI) who receive percutaneous coronary intervention (PCI) remains a topic of ongoing debate. Current guidelines on BP management lack specific recommendations for STEMI patients undergoing PCI, resulting in substantial individual variability and uncertainties in clinical treatment strategies. This research seeks to determine the ideal BP levels linked to the lowest risk of in-hospital mortality and long-term adverse endpoints in STEMI patients receiving PCI. Methods: This retrospective study analyzed data from the China Acute Myocardial Infarction (CAMI) Registry, enrolling 10,482 STEMI patients undergoing PCI at 108 Chinese hospitals from January 2013 to September 2014. The primary outcome was in-hospital mortality. Secondary outcomes included 2-year all-cause mortality, severe bleeding, and major adverse cardiac and cerebrovascular events (MACCEs), defined as a combination of all-cause mortality, myocardial infarction (MI), or stroke. The analysis of the relationship between admission systolic blood pressure (SBP)/diastolic blood pressure (DBP) and the primary and secondary outcomes as continuous and categorical variables was conducted using restricted cubic spline (RCS) analysis and Cox regression models. Results: RCS analysis revealed that a J-shaped association existed between admission SBP/DBP and the risk of the primary outcome, with significant nonlinearity (both p < 0.001). Both lower and higher SBP/DBP levels were linked to an elevated risk of in-hospital mortality. The ideal SBP/DBP levels to minimize the in-hospital mortality risk were 157/94 mmHg. Compared to the reference SBP/DBP group (120–129/70–79 mmHg), lower admission SBP (<109 mmHg) or DBP (60–69 mmHg) significantly elevated the risk of the primary outcome. The adjusted hazard ratio (HR) for SBP levels of 100–109 mmHg and <100 mmHg was 1.08 (95% confidence interval (CI): 1.00–1.17; p = 0.0395 and p = 0.043, respectively), and for DBP of 60–69 mmHg, the adjusted HR was 1.07 (95% CI: 1.01–1.14, p = 0.0305). Similarly, the J-shaped curve was also noted between SBP/DBP and secondary outcomes, such as all-cause mortality, severe bleeding and MACCEs. However, no significant non–linear relationship was observed between SBP/DBP and recurrent MI at 2-year follow-up. Conclusions: Among STEMI patients undergoing PCI, a J-curve relationship in in-hospital mortality was observed with a nadir at 157/94 mmHg. Similar J-shaped trends were also observed for secondary outcomes including all-cause mortality, severe bleeding and MACCEs. However, no significant nonlinear correlation was found between admission BP and recurrent MI within 2 years. Clinical Trial Registration: NCT01874691, https://www.clinicaltrials.gov/study/NCT01874691?term=NCT01874691&rank=1.

21 August 2025 in Journal of Clinical & Translational Endocrinology
Verified
Journal Article
Open access
YLYilu Liu
Yilu Liu
HYHongzhao You
Hongzhao You
YZYingxuan Zhu
Yingxuan Zhu
FLFang Luo
Fang Luo
YZYanyan Zhao
Yanyan Zhao
WYWeixian Yang
Weixian Yang
To characterize the complex relationships of body mass index (BMI) and triglyceride-glucose index (TyG) with 5-year all-cause mortality in patients with diabetes mellitus and comorbid hypertension. Overall, 5,728 patients from the 1999-2014 US National Health and Nutrition Examination Survey (NHANES) cycles and 3,456 from the 2005-2010 China Kailuan cycles were included. TyG was calculated as the logarithmic product of the fasting triglyceride and glucose concentrations. The prevalence of 5-year all-cause mortality was 8.4 % in the NHANES population and 9.2 % in the Kailuan cohort. TyG mediated the association between BMI and all-cause mortality, being responsible for 38.4 % in the NHANES database and 41.6 % in the Kailuan cohort. Significant multiplicative effects were identified between TyG and BMI, which were closer for patients with high BMI. When stratified by BMI and TyG, high-risk subgroups were identified and had higher risks of all-cause mortality than the intermediate- and low-risk subgroups (both log-rank P < 0.001). TyG mediated a considerable proportion of the effect of BMI on all-cause mortality in patients with diabetes and hypertension. The combination of BMI and TyG could be useful for the risk stratification of all-cause mortality. Measures aimed at weight loss might reduce the all-cause mortality risk associated with insulin resistance.

9 March 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
MYMiao Yu
Miao Yu
YJYu Jiang
Yu Jiang
YSYu Sun
Yu Sun
HZHan Zhang
Han Zhang
TWTian-Jie Wang
Tian-Jie Wang
WYWeixian Yang
Weixian Yang
In-stent restenosis (ISR) remains a major clinical challenge despite advances in stent technology and pharmacotherapy. While inflammation plays a pivotal role in ISR progression, the prognostic value of stable biomarkers reflecting chronic inflammation has not been fully explored. This study examined the association of serum total bilirubin (TBIL), alone and in combination with high-sensitivity C-reactive protein (hsCRP), with long-term cardiovascular outcomes in ISR patients undergoing percutaneous coronary intervention (PCI). A total of 2055 ISR patients who underwent repeat PCI at Fuwai Hospital from January 2017 to December 2018 were consecutively enrolled. Patients were stratified based on TBIL and hsCRP levels. The primary endpoint was the incidence of major adverse cardiovascular events (MACEs), including all-cause mortality, myocardial infarction, stroke, repeat revascularization and stent thrombosis. Multivariable Cox regression and subgroup analyses were conducted. During a median follow-up of 36 months, 457 patients suffered from MACEs. Lower TBIL levels were independently associated with a higher risk of long-term MACEs, regardless of high hsCRP (hsCRP ≥ 2 mg/L, hazard ratio [HR] = 1.865, 95% confidence interval [CI] 1.423–2.443, P < 0.001) or low hsCRP (hsCRP < 2 mg/L HR = 1.338, 95% CI: 1.039–1.721, P = 0.024). Kaplan-Meier curves showed that patients with both low TBIL and elevated hsCRP had the highest incidence of MACEs (P < 0.001). The combination of TBIL and hsCRP provided additional risk stratification information, especially in patients with diabetes mellitus (P for interaction = 0.001). Serum TBIL is a novel, independent predictor of adverse outcomes in ISR patients and provides complementary value to hsCRP for risk stratification. Its clinical utility may be particularly valuable in diabetic populations, suggesting that TBIL may help identify higher-risk subgroups within ISR populations. This study is not a registered clinical trial. Clinical trial registration: not applicable. The online version contains supplementary material available at 10.1186/s12872-026-05680-5.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
FTFangshun Tan
Fangshun Tan
YJYu Jiang
Yu Jiang
RWRuizhi Wang
Ruizhi Wang
ZHZiquan Hu
Ziquan Hu
YXYuting Xia
Yuting Xia
WYWeixian Yang
Weixian Yang
Background: Psoriasis (PSO) and atherosclerosis (AS) are chronic inflammatory diseases that frequently coexist, with each condition exacerbating the other. However, the underlying mechanisms remain poorly understood, partly due to the lack of a suitable animal model that recapitulates this bidirectional comorbidity. Methods: PSO‐AS mouse models were constructed by combining high‐fat diet (HFD)–induced AS with imiquimod (IMQ)‐triggered psoriatic inflammation in ApoE −/− mice. PSO severity was assessed via skin manifestation, hematoxylin and eosin (H&E) staining, PSO area and severity index (PASI) score, quantitative real‐time PCR (qRT‐PCR), and serum ELISA, while AS was assessed by en face Oil red O (ORO) staining of aorta, H&E staining, ORO staining, Sirius Red (SR) staining, and immunofluorescence (IF) staining of the aortic root section. Mechanistic insights were obtained via proteomics, machine learning (ML), and validation of macrophage polarization in both skin and plaques. Results: Chronic PSO model more closely resembles real‐world conditions than acute PSO model. Combining the IMQ application with a HFD, both the PSO‐AS group and the PSO group developed obvious psoriatic skin lesion, but the PSO‐AS group showed the highest epidermal thickness, PASI scores, and expression levels of psoriatic biomarkers (Interleukin‐17A [IL‐17A] and Interleukin‐23 [IL‐23]) and inflammatory factors (e.g., tumor necrosis factor alpha [TNF‐α] and Interleukin‐6 [IL‐6]), implying that AS may exacerbate PSO. Similarly, the PSO‐AS and AS groups both developed obvious plaque in the aorta, while the PSO‐AS group has the largest plaque area, necrotic core (NC) area, lipid content with the least fibrous cap (FC) thickness, and collagen content, illustrating that PSO conspicuously aggravated AS progression and led to an unstable plaque shift. Statistical analysis also confirms that PSO and AS mutually exacerbate each other, forming a vicious cycle that may be strongly associated with IL‐17. Proteomics and ML revealed marked M1 macrophage polarization in PSO‐AS mice. Validation by Western blot and IF showed upregulated M1 markers (CD86) and downregulated M2 markers (CD163) in both skin lesions and aortic roots, indicating that M1‐skewed macrophages fuel the vicious cycle. Besides, we explore that IFIT3 may serve as a promising biomarker for M1 macrophages in PSO‐AS skin. Conclusions: This novel PSO‐AS mouse model faithfully recapitulates the bidirectional exacerbation seen clinically and uncovers M1 macrophage polarization as a key driver of this comorbidity. The model provides a robust platform for mechanistic and therapeutic studies of PSO‐associated cardiovascular disease (CVD).

20 May 2026 in Food & Nutrition Research
Verified
Journal Article
Open access
PDF file
YXYing Xiao
Ying Xiao
HYHongzhao You
Hongzhao You
TWTianjie Wang
Tianjie Wang
YZYan Zeng
Yan Zeng
YZYingxuan Zhu
Yingxuan Zhu
WYWeixian Yang
Weixian Yang
Background: Cardiovascular–kidney–metabolic (CKM) syndrome is a progressive, five-stage disease framework driven by interrelated cardiovascular, renal, and metabolic dysfunction, with chronic inflammation and insulin resistance (IR) playing key roles. The dietary inflammatory index (DII) quantifies overall dietary inflammatory potential, but its role in CKM staging remains unclear. Objective: This study aimed to evaluate the association between DII and CKM syndrome stage and to assess the potential mediating effect of IR. Design: This cross-sectional study used data from the National Health and Nutrition Examination Survey (2007–2018). DII was derived from 24-h dietary recall. CKM stages were defined by the American Heart Association criteria. IR was assessed using the triglyceride–glucose index (TyG), Metabolic Score for IR (METS-IR), and Homeostatic Model Assessment for IR (HOMA-IR). Statistical analyses were performed after accounting for the complex survey design. Results: Of the 27,635 participants, 94.08% had CKM syndrome (Stage 1 or higher). Compared with Stage 0, stepwise increases in the adjusted odds ratios for a higher DII score were observed across CKM stages (Q4 vs. Q1: 1.67 [1.31–2.15] for Stage 1; 2.11 [1.63–2.73] for Stage 2; 2.32 [1.08–4.98] for Stage 3; and 4.19 [2.65–6.63] for Stage 4). Restricted cubic splines models confirmed the positive linear association between DII and each CKM stage (all Poverall < 0.05; Pnon-linear > 0.05), with increasingly steep slopes at higher stages. TyG, METS-IR, and HOMA-IR mediated 30.7, 45.0, and 25.3% of the association between DII and CKM syndrome stage, respectively. Conclusions: Pro-inflammatory diet, as indicated by a higher DII score, was positively associated with more advanced CKM syndrome stage, partly mediated by IR. The DII may serve as a practical measure of dietary inflammation in CKM management.